Title:
USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES
Document Type and Number:
WIPO Patent Application WO/2011/102149
Kind Code:
A1
Abstract:
This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of immune disease or allergy in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.
More Like This:
Inventors:
KANAZAWA KIYOSHI (JP)
NONOMURA KAZUHIKO (JP)
OKUMURA TAKAKO (JP)
KOIZUMI SHINICHI (JP)
NONOMURA KAZUHIKO (JP)
OKUMURA TAKAKO (JP)
KOIZUMI SHINICHI (JP)
Application Number:
PCT/JP2011/000994
Publication Date:
August 25, 2011
Filing Date:
February 22, 2011
Export Citation:
Assignee:
RAQUALIA PHARMA INC (JP)
KANAZAWA KIYOSHI (JP)
NONOMURA KAZUHIKO (JP)
OKUMURA TAKAKO (JP)
KOIZUMI SHINICHI (JP)
KANAZAWA KIYOSHI (JP)
NONOMURA KAZUHIKO (JP)
OKUMURA TAKAKO (JP)
KOIZUMI SHINICHI (JP)
International Classes:
A61K45/00; A61K31/38; A61K31/437; A61K31/44; A61K31/4412; A61K31/443; A61P1/00; A61P17/00; A61P37/00; A61P37/08; A61P43/00
Foreign References:
| JP2004517054A | 2004-06-10 | |||
| JP2007504210A | 2007-03-01 | |||
| JP2007536366A | 2007-12-13 | |||
| JP2006516600A | 2006-07-06 | |||
| JP2010500293A | 2010-01-07 |
Other References:
YAO,C ET AL.: "Prostaglandin E2-EP4 signaling promotes immune inflammation though TH1 cell differentiation and TH17 cell expansion", NATURE MEDICINE, vol. 15, no. 6, 2009, pages 633 - 640
CHEN,Q. ET AL.: "A novel antagonist of the prostaglandin E2EP4 receptor inhibits Thl differentiation and Th17 expansion and is orally active in arthritis models", BRITISH JOURNAL OF PHARMACOLOGY, vol. 160, no. 2, May 2010 (2010-05-01), pages 292 - 310
See also references of EP 2538978A4
CHEN,Q. ET AL.: "A novel antagonist of the prostaglandin E2EP4 receptor inhibits Thl differentiation and Th17 expansion and is orally active in arthritis models", BRITISH JOURNAL OF PHARMACOLOGY, vol. 160, no. 2, May 2010 (2010-05-01), pages 292 - 310
See also references of EP 2538978A4
Attorney, Agent or Firm:
IWATANI, Ryo (1-31 Dojima 2-chome, Kita-k, Osaka-shi Osaka 03, JP)
Download PDF:
Claims: